ReviewAmerican journal of nuclear medicine and molecular imaging2015
Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.
Review in American journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Assessment and Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Pooled it
- Value ofEuropean radiology · 2023Trial
- Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluating [Journal of market access & health policy · 2026Article
- Unexpected brain metastases from neuroendocrine prostate cancer detected by [Frontiers in medicine · 2026Article
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Radiopharmaceuticals for Skeletal Muscle PET Imaging.International journal of molecular sciences · 2024Review
- BBB opening with focused ultrasound in nonhuman primates and Parkinson's disease patients: Targeted AAV vector delivery and PET imaging.Science advances · 2023Article
- Feasibility ofDiagnostics (Basel, Switzerland) · 2022Article
- Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.Frontiers in chemistry · 2022Review
- Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.Arab journal of urology · 2020Review
- Article
- Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands.American journal of nuclear medicine and molecular imaging · 2019Review
- Clinical implications of PET/CT in prostate cancer management.Translational andrology and urology · 2018Review
- Upcoming imaging concepts and their impact on treatment planning and treatment response in radiation oncology.Radiation oncology (London, England) · 2018Article
- 18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer.Prostate international · 2018Article
- Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.American journal of nuclear medicine and molecular imaging · 2018Review
- A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.Molecular imaging and biology · 2017Article
- Article
- Lymph node imaging in initial staging of prostate cancer: An overview and update.World journal of radiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While (18)F-Fluorodeoxyglucose ((18)F-FDG) Positron-Emission Tomography (PET) has limited value in prostate cancer (PCa), it may be useful for specific subgroups of PCa patients with hormone-resistant poorly differentiated cell types. (18)F-Fluorocholine ((18)F-FCH) PET/CT has been increasingly used in primary and recurrent PCa and has been shown to add valuable information. Although there is a correlation between the foci of activity and the areas of malignancy in the prostate gland, the clinical value of (18)F-FCH is still controversial for detection of the malignant focus in the prostate. For the T-staging of PCa at diagnosis the value of (18)F-FCH is limited. This is probably due to limited resolution of PET system and positive findings in benign prostate diseases. Conversely, (18)F-FCH PET/CT is a promising imaging modality for the delineation of local and distant nodal recurrence and bone metastases and is poised to have an impact on therapy management. In this review, recent studies of (18)F-FCH PET/CT in PCa are summarized.
Indexed as
Identifiers
25973332PMC4396012W244971556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.